Zobrazeno 1 - 10
of 152
pro vyhledávání: '"Hideki Aizaki"'
Independent evolution of multi-dominant viral genome species observed in a hepatitis C virus carrier
Autor:
Tomomi Ando, Hideki Aizaki, Masaya Sugiyama, Tomoko Date, Kazuhiko Hayashi, Masatoshi Ishigami, Yoshiaki Katano, Hidemi Goto, Masashi Mizokami, Masamichi Muramatsu, Makoto Kuroda, Takaji Wakita
Publikováno v:
Biochemistry and Biophysics Reports, Vol 32, Iss , Pp 101327- (2022)
The viral genome quasispecies composition of hepatitis C virus (HCV) could have important implications to viral pathogenesis and resistance to anti-viral treatment. The purpose of the present study was to profile the HCV RNA quasispecies. We develope
Externí odkaz:
https://doaj.org/article/d8441385e61544af99cc5acf4fcc144c
Autor:
Kousho Wakae, Satoru Kondo, Hai Thanh Pham, Naohiro Wakisaka, Lusheng Que, Yingfang Li, Xin Zheng, Kento Fukano, Kouichi Kitamura, Koichi Watashi, Hideki Aizaki, Takayoshi Ueno, Makiko Moriyama‐Kita, Kazuya Ishikawa, Yosuke Nakanishi, Kazuhira Endo, Masamichi Muramatsu, Tomokazu Yoshizaki
Publikováno v:
Cancer Medicine, Vol 9, Iss 20, Pp 7663-7671 (2020)
Abstract An Epstein‐Barr virus (EBV)—encoded latent membrane protein 1 (LMP1) is a principal oncogene that plays a pivotal role in EBV‐associated malignant tumors including nasopharyngeal cancer (NPC). Recent genomic landscape studies revealed
Externí odkaz:
https://doaj.org/article/859790dc96a14dbbbe84499aed70ca2b
Autor:
Hiroshi Yokokawa, Midori Shinohara, Yuji Teraoka, Michio Imamura, Noriko Nakamura, Noriyuki Watanabe, Tomoko Date, Hideki Aizaki, Tomokatsu Iwamura, Hideki Narumi, Kazuaki Chayama, Takaji Wakita
Publikováno v:
PLoS ONE, Vol 17, Iss 9, p e0274283 (2022)
In recent years, new direct-acting antivirals for hepatitis C virus (HCV) have been approved, but hepatitis C continues to pose a threat to human health. It is important to develop neutralizing anti-HCV antibodies to prevent medical and accidental in
Externí odkaz:
https://doaj.org/article/eb687d3a76cf48d9a935c8025f9c022f
Autor:
Chisa Kobayashi, Yoshihiro Watanabe, Mizuki Oshima, Tomoyasu Hirose, Masako Yamasaki, Masashi Iwamoto, Masato Iwatsuki, Yukihiro Asami, Kouji Kuramochi, Kousho Wakae, Hideki Aizaki, Masamichi Muramatsu, Camille Sureau, Toshiaki Sunazuka, Koichi Watashi
Publikováno v:
Viruses, Vol 14, Iss 4, p 764 (2022)
Current anti-hepatitis B virus (HBV) drugs are suppressive but not curative for HBV infection, so there is considerable demand for the development of new anti-HBV agents. In this study, we found that fungus-derived exophillic acid inhibits HBV infect
Externí odkaz:
https://doaj.org/article/9670e2105fe742b1a5396a01e8c5fe35
Autor:
Aya Ishizaka, Michiko Koga, Taketoshi Mizutani, Lay Ahyoung Lim, Eisuke Adachi, Kazuhiko Ikeuchi, Ryuta Ueda, Haruyo Aoyagi, Satoshi Tanaka, Hiroshi Kiyono, Tetsuro Matano, Hideki Aizaki, Sachiyo Yoshio, Eiji Mita, Masamichi Muramatsu, Tatsuya Kanto, Takeya Tsutsumi, Hiroshi Yotsuyanagi
Publikováno v:
Viruses, Vol 13, Iss 10, p 2101 (2021)
Hepatitis A virus (HAV) causes transient acute infection, and little is known of viral shedding via the duodenum and into the intestinal environment, including the gut microbiome, from the period of infection until after the recovery of symptoms. The
Externí odkaz:
https://doaj.org/article/08f8d08e447d42998bae786d1fb46ec6
Autor:
Kento Fukano, Senko Tsukuda, Mizuki Oshima, Ryosuke Suzuki, Hideki Aizaki, Mio Ohki, Sam-Yong Park, Masamichi Muramatsu, Takaji Wakita, Camille Sureau, Yuki Ogasawara, Koichi Watashi
Publikováno v:
Frontiers in Microbiology, Vol 9 (2019)
Current anti-hepatitis B virus (HBV) agents, which include nucleos(t)ide analogs and interferons, can significantly suppress HBV infection. However, there are limitations in the therapeutic efficacy of these agents, indicating the need to develop ant
Externí odkaz:
https://doaj.org/article/999276080e50410996242278a4d6bc65
Autor:
Takeya Tsutsumi, Kazuya Okushin, Kenichiro Enooku, Hidetaka Fujinaga, Kyoji Moriya, Hiroshi Yotsuyanagi, Hideki Aizaki, Tetsuro Suzuki, Yoshiharu Matsuura, Kazuhiko Koike
Publikováno v:
PLoS ONE, Vol 12, Iss 1, p e0170461 (2017)
The hepatitis C virus nonstructural protein NS5A is involved in resistance to the host immune response, as well as the viral lifecycle such as replication and maturation. Here, we established transgenic mice expressing NS5A protein in the liver and e
Externí odkaz:
https://doaj.org/article/24db7b9269054744ac4dfd7f39b67970
Autor:
Akihito Tsubota, Kaoru Mogushi, Hideki Aizaki, Ken Miyaguchi, Keisuke Nagatsuma, Hiroshi Matsudaira, Tatsuya Kushida, Tomomi Furihata, Hiroshi Tanaka, Tomokazu Matsuura
Publikováno v:
PLoS ONE, Vol 9, Iss 5, p e97078 (2014)
Despite advances in chronic hepatitis C treatment, a proportion of patients respond poorly to treatment. This study aimed to explore hepatic mRNA and microRNA signatures involved in hepatitis C treatment resistance. Global hepatic mRNA and microRNA e
Externí odkaz:
https://doaj.org/article/3db261d955cf4f138548473a638d8423
Autor:
Ryosuke Suzuki, Mami Matsuda, Koichi Watashi, Hideki Aizaki, Yoshiharu Matsuura, Takaji Wakita, Tetsuro Suzuki
Publikováno v:
PLoS Pathogens, Vol 9, Iss 8, p e1003589 (2013)
Hepatitis C virus (HCV) nonstructural protein 2 (NS2) is a hydrophobic, transmembrane protein that is required not only for NS2-NS3 cleavage, but also for infectious virus production. To identify cellular factors that interact with NS2 and are import
Externí odkaz:
https://doaj.org/article/a0668f3b0c3e4bf98fae0795c1c77def
Autor:
Yoshihiro Matsumoto, Tomokazu Matsuura, Haruyo Aoyagi, Mami Matsuda, Su Su Hmwe, Tomoko Date, Noriyuki Watanabe, Koichi Watashi, Ryosuke Suzuki, Shizuko Ichinose, Kenjiro Wake, Tetsuro Suzuki, Tatsuo Miyamura, Takaji Wakita, Hideki Aizaki
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68992 (2013)
Glycyrrhizin (GL) has been used in Japan to treat patients with chronic viral hepatitis, as an anti-inflammatory drug to reduce serum alanine aminotransferase levels. GL is also known to exhibit various biological activities, including anti-viral eff
Externí odkaz:
https://doaj.org/article/161a0ca955a641a2968eb12862ddc32e